NeoTherapeutics outlines plans for Neotrofin

NEOT said it will discontinue low-dose studies of its Neotrofin leteprinim oral small molecule, which increases mRNA for neurotrophic factors, after a Phase IIb study of 150 mg doses given for 90 days...